Named Bioactive Compounds · Compound
Chloranthalactone
Moderate Evidencecompound4 PubMed Studies
Hermetica Superfood Encyclopedia
Chloranthalactone refers to a group of sesquiterpenoid lactones — including variants A, B, and E — isolated primarily from plants in the Chloranthus genus. Chloranthalactone E demonstrates anti-inflammatory activity by inhibiting nitric oxide production in vitro, while Chloranthalactone B is classified as an anti-inflammatory agent, though its precise molecular mechanism remains under investigation.
Chloranthalactone refers to a family of sesquiterpenoid lactones (primarily types A, B, and E) isolated from the roots or aerial parts of Chloranthus serratus, a shrub native to East Asia. These compounds are extracted using solvents like chloroform, dichloromethane, or ethyl acetate and are available as reference standards in powder form.
No human clinical trials, randomized controlled trials, or meta-analyses have been conducted on chloranthalactone compounds. Research is limited exclusively to in vitro studies and chemical synthesis efforts, with no clinical data or PubMed PMIDs available.
No clinically studied dosage ranges have been established for any form of chloranthalactone, as no human trials exist. Safety profiles and therapeutic doses remain completely unestablished. Consult a healthcare provider before starting any new supplement.
Chloranthalactones are a group of sesquiterpenoid lactones (specifically lindenane-type sesquiterpenes) isolated primarily from plants of the genus Chloranthus (family Chloranthaceae), such as Chloranthus japonicus, Chloranthus serratus, and Chloranthus glaber. They are not nutritional compounds and have no conventional nutritional profile. Key details: • Classification: Terpenoid secondary metabolites (sesquiterpene lactones); multiple variants identified including Chloranthalactone A, B, C, D, E, F, and dimeric forms • Molecular characteristics: Typically C15 sesquiterpenoid skeletons featuring a lactone (γ-butyrolactone or δ-valerolactone) ring system; molecular weights generally in the range of ~230–500 Da depending on monomeric vs. dimeric forms • Concentrations in source plants: Present in trace quantities (typically microgram-to-low-milligram per kilogram of dried plant material); exact concentrations vary by species, plant part (roots, stems, leaves), and extraction method • Bioactive compound nature: These are exclusively bioactive phytochemicals with no macronutrient (protein, fat, carbohydrate), vitamin, or mineral content; they are not consumed as food or dietary supplements • Key structural variants and approximate molecular weights: Chloranthalactone A (~232 Da), Chloranthalactone B (~248 Da), Chloranthalactone E (~246 Da); dimeric chloranthalactones can exceed 450 Da • Bioavailability: No human pharmacokinetic or bioavailability data exist; as lipophilic sesquiterpene lactones, they are expected to have limited aqueous solubility and likely undergo extensive hepatic first-pass metabolism; the lactone moiety may be susceptible to hydrolysis under physiological pH conditions • Solubility: Lipophilic; typically extracted using organic solvents (ethanol, methanol, ethyl acetate, chloroform) • No established dietary reference intake, recommended daily allowance, or safe consumption levels exist • These compounds are strictly of pharmacological/phytochemical research interest and are not present in any recognized food, supplement, or nutritional product • No fiber, protein, carbohydrate, fat, vitamin, or mineral content applicable
Chloranthalactone E inhibits the production of nitric oxide (NO), likely through suppression of inducible nitric oxide synthase (iNOS) activity in macrophage-like cell models, reducing pro-inflammatory signaling cascades. Chloranthalactone B is categorized as an anti-inflammatory agent, though the specific receptor targets, enzyme interactions, or downstream pathways — such as NF-κB or MAPK inhibition — have not yet been formally characterized in published research. The sesquiterpenoid lactone scaffold common to these compounds may interact with thiol groups on inflammatory proteins, a mechanism seen in structurally related compounds, but this remains speculative for chloranthalactones specifically.
Research on chloranthalactone compounds is limited exclusively to in vitro (cell-based) studies, with no published human clinical trials or animal intervention studies identified to date. The anti-inflammatory activity of Chloranthalactone E has been demonstrated in laboratory settings measuring NO inhibition, but no quantified IC50 values or standardized assay data are widely reported in accessible literature. Chloranthalactone B's classification as an anti-inflammatory agent appears based on preliminary phytochemical screening rather than rigorous mechanistic or dose-response studies. The overall evidence base is insufficient to draw conclusions about efficacy, optimal dosage, or therapeutic relevance in humans.
No formal human safety studies, toxicology profiles, or adverse event reports exist for chloranthalactone in the published literature. Drug interaction potential is entirely unknown, as no pharmacokinetic studies have characterized chloranthalactone's metabolism, protein binding, or cytochrome P450 interactions. Chloranthalactone is contraindicated in pregnancy and lactation by default due to a complete absence of safety data in these populations. Individuals with known sesquiterpene lactone sensitivities — such as those with allergies to Asteraceae family plants — should exercise caution, as cross-reactivity with structurally similar compounds is theoretically possible.
